MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma

Item

http://www.wikidata.org/entity/Q37709001

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma

@en

MTOR inhibition reversed drug ...... otinib in lung adenocarcinoma.

@nl

type

Item

label

MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma

@en

MTOR inhibition reversed drug ...... otinib in lung adenocarcinoma.

@nl

prefLabel

MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma

@en

MTOR inhibition reversed drug ...... otinib in lung adenocarcinoma.

@nl

P1476

MTOR inhibition reversed drug ...... lotinib in lung adenocarcinoma

@en

P2093

Hongqing Zhuang

http://www.w3.org/2001/XMLSchema#string

Jing Bai

http://www.w3.org/2001/XMLSchema#string

Joe Y Chang

http://www.w3.org/2001/XMLSchema#string

Ping Wang

http://www.w3.org/2001/XMLSchema#string

Zhiyong Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumors to radiotherapy

Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response.

Experimental study on the regulation of erlotinib-induced radiosensitization with an anti-c-MET monoclonal antibody

Research progress on criteria for discontinuation of EGFR inhibitor therapy.

Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer

Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis.

Biliverdin reductase: PKC interaction at the cross-talk of MAPK and PI3K signaling pathways.

P304

84688-84694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12423

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27713162

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5356691

http://www.w3.org/2001/XMLSchema#string